We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Ocular Surface Disease in Glaucoma Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00382122
First Posted: September 28, 2006
Last Update Posted: May 28, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Alcon Research
  Purpose
Demographic information and a brief medical and concomitant medicine history will be obtained from the glaucoma patient's records. Qualified patients will be asked to complete a questionnaire about their symptoms. Patients will then be scheduled to undergo three standard clinical tests of the ocular surface.

Condition Phase
Glaucoma Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Prevalence of Ocular Surface Disease in Glaucoma Patients

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Enrollment: 101
Study Start Date: September 2006
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients 18 years or older with open-angle glaucoma or ocular hypertension were consecutively recruited for the study.
Criteria

Inclusion Criteria:

  • Diagnosis of glaucoma;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Inability to understand trial procedures;
  • Inability to understand Informed Consent;
  • Current use or use within the last 3 months of Restasis, steroids, or topical ocular non-steroidal anti-inflammatory drugs;
  • Punctal plugs;
  • Previous glaucoma, corneal, or conjunctival surgery;
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00382122


Locations
United States, California
La Jolla
La Jolla, California, United States, 92093
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Felipe Medeiros, MD, PhD University of California, San Diego
  More Information

Publications:
Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00382122     History of Changes
Other Study ID Numbers: CMS-06-06
First Submitted: September 27, 2006
First Posted: September 28, 2006
Last Update Posted: May 28, 2012
Last Verified: September 2007

Keywords provided by Alcon Research:
Glaucoma
Ocular hypertension
Dry eye
Ocular surface disease

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases